← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Dermaxon, Llc
Missoula, MT
$3,278,461
Total funding
8
Grants
Funding over time
peak $1.2M · FY2013–24$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,278,461 · 8
By mechanism
R44$1,499,868 · 1
R41$1,258,171 · 5
R43$520,422 · 2
Investigators at Dermaxon, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Selective inhibition of CYP26A1 in the skin for the treatment of ichthyosis$937,253
R44 · FY2019 · AR
Selective inhibition of CYP26A1 in the skin for the treatment of ichthyosis$536,029
R44 · FY2018 · AR
Novel therapeutic target to combat cutaneous lupus$298,132
R41 · FY2021 · TR
Selective CYP26 inhibitors for the oral treatment of recalcitrant nodular acne.$295,423
R43 · FY2023 · AR
Targeting retinoid acid metabolic pathways to treat noise-induced hearing loss$290,920
R41 · FY2024 · DC
Topical selective T-type blockers for the treatment of neuropathic pain$228,479
R41 · FY2018 · NS
Inhibition of retinoic acid metabolism for reversal of cognitive deficits in AD$225,000
R41 · FY2013 · AG
Topical selective T-type blockers for the treatment of pruritus$224,999
R43 · FY2019 · AR
Selective inhibition of CYP26A1 in the skin for the treatment of ichthyosis$215,640
R41 · FY2016 · AR
Selective inhibition of CYP26A1 in the skin for the treatment of ichthyosis$26,586
R44 · FY2019 · AR